Halozyme Therapeutics, Inc. (LON:0J2O)
London
· Delayed Price · Currency is GBP · Price in USD 57.93
+1.42 (2.52%)
At close: Feb 21, 2025
Halozyme Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Cash & Equivalents | 115.85 | 118.37 | 234.2 | 118.72 | 147.7 | Upgrade
|
| Short-Term Investments | 480.22 | 217.63 | 128.6 | 622.2 | 220.31 | Upgrade
|
| Cash & Short-Term Investments | 596.07 | 336 | 362.79 | 740.92 | 368.01 | Upgrade
|
| Cash Growth | 77.40% | -7.39% | -51.03% | 101.33% | -12.64% | Upgrade
|
| Receivables | 308.46 | 234.21 | 231.07 | 90.98 | 97.73 | Upgrade
|
| Inventory | 141.86 | 127.6 | 100.12 | 53.91 | 60.75 | Upgrade
|
| Prepaid Expenses | 38.95 | 48.61 | 45.02 | 40.48 | 28.27 | Upgrade
|
| Total Current Assets | 1,085 | 746.42 | 739.01 | 926.29 | 554.76 | Upgrade
|
| Property, Plant & Equipment | 75.04 | 74.94 | 75.57 | 8.79 | 10.59 | Upgrade
|
| Goodwill | 416.82 | 416.82 | 409.05 | - | - | Upgrade
|
| Other Intangible Assets | 401.83 | 472.88 | 546.65 | - | - | Upgrade
|
| Long-Term Deferred Tax Assets | 3.86 | 4.39 | 44.43 | 155.43 | - | Upgrade
|
| Other Long-Term Assets | 80.6 | 17.82 | 26.8 | 13.91 | 14.57 | Upgrade
|
| Total Assets | 2,063 | 1,733 | 1,842 | 1,104 | 579.92 | Upgrade
|
| Accounts Payable | 10.25 | 11.82 | 17.69 | 1.54 | 1.93 | Upgrade
|
| Accrued Expenses | 121.8 | 100.68 | 97.66 | 22.17 | 19.08 | Upgrade
|
| Current Portion of Long-Term Debt | - | - | 13.33 | 89.42 | 397.23 | Upgrade
|
| Current Portion of Leases | 7.05 | - | 2.1 | 2.28 | 1.4 | Upgrade
|
| Current Unearned Revenue | - | - | - | 1.75 | 1.75 | Upgrade
|
| Total Current Liabilities | 139.1 | 112.49 | 130.79 | 117.15 | 421.39 | Upgrade
|
| Long-Term Debt | 1,506 | 1,499 | 1,493 | 787.26 | - | Upgrade
|
| Long-Term Leases | 23.65 | 32.2 | 32.69 | 0.54 | 3.47 | Upgrade
|
| Long-Term Unearned Revenue | - | - | - | 2.53 | 4.03 | Upgrade
|
| Other Long-Term Liabilities | 31.11 | 5.52 | 15.47 | - | - | Upgrade
|
| Total Liabilities | 1,700 | 1,649 | 1,672 | 907.48 | 428.88 | Upgrade
|
| Common Stock | 0.12 | 0.13 | 0.14 | 0.14 | 0.14 | Upgrade
|
| Additional Paid-In Capital | - | 2.41 | 27.37 | 256.35 | 625.48 | Upgrade
|
| Retained Earnings | 359.87 | 90.55 | 143.22 | -58.91 | -474.59 | Upgrade
|
| Comprehensive Income & Other | 3.83 | -9.28 | -0.92 | -0.62 | 0.02 | Upgrade
|
| Shareholders' Equity | 363.82 | 83.81 | 169.8 | 196.95 | 151.05 | Upgrade
|
| Total Liabilities & Equity | 2,063 | 1,733 | 1,842 | 1,104 | 579.92 | Upgrade
|
| Total Debt | 1,537 | 1,531 | 1,541 | 879.49 | 402.1 | Upgrade
|
| Net Cash (Debt) | -940.43 | -1,195 | -1,178 | -138.57 | -34.08 | Upgrade
|
| Net Cash Per Share | -7.27 | -8.91 | -8.38 | -0.94 | -0.24 | Upgrade
|
| Filing Date Shares Outstanding | 123.15 | 126.82 | 135.37 | 137.7 | 135.21 | Upgrade
|
| Total Common Shares Outstanding | 123.14 | 126.77 | 135.15 | 137.5 | 134.97 | Upgrade
|
| Working Capital | 946.24 | 633.93 | 608.22 | 809.14 | 133.38 | Upgrade
|
| Book Value Per Share | 2.95 | 0.66 | 1.26 | 1.43 | 1.12 | Upgrade
|
| Tangible Book Value | -454.83 | -805.89 | -785.9 | 196.95 | 151.05 | Upgrade
|
| Tangible Book Value Per Share | -3.69 | -6.36 | -5.81 | 1.43 | 1.12 | Upgrade
|
| Machinery | 59.28 | 50.78 | 43.13 | 18.26 | 17.25 | Upgrade
|
| Leasehold Improvements | 7.01 | 6.99 | 6.73 | 1.63 | 1.63 | Upgrade
|
| Order Backlog | 99.9 | - | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.